Glioblastoma: trials for referral
457 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 457 open trials.
Phase 1/21 site
Not yet recruitingUnited States
NCT07389278
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Sabine Mueller, MD, PhD
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/239 sites
RecruitingUnited States
NCT05432804
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingAustralia, Uzbekistan
NCT07524140
A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
Eilean Therapeutics
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited Kingdom
NCT07356973
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
CRISM Therapeutics LTD
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 322 sites
RecruitingUnited States
NCT07195591
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
GT Medical Technologies, Inc.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT06161519
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Cancer Institute (NCI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 111 sites
RecruitingBelgium, Switzerland, France, United Kingdom, Japan, United States
NCT06641908
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingCanada
NCT04765098
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingUnited States
NCT05139056
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
City of Hope Medical Center
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingUnited States
NCT07464925
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07909811
Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma
Unity Health Toronto
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT05106296
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Theodore S. Johnson
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingChina
NCT07180927
DLL3 CAR-T Therapy Targeting Brain Tumors
Shenzhen Geno-Immune Medical Institute
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govNo phase4 sites
Not yet recruitingSouth Korea
NCT07831161
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
Dong-A University Hospital
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 238 sites
RecruitingUnited States
NCT07326566
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 2/364 sites
RecruitingAustralia, Canada, Switzerland, Germany, France, United States
NCT03970447
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research
Pre-treatment window Registry sentence: “Received any prior treatment for glioma including: a.”
Registry updated 2 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govEarly Phase 11 site
Not yet recruitingAustralia
NCT07908147
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
Olivia Newton-John Cancer Research Institute
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT06946680
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
University of Florida
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07301268
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 19 sites
RecruitingUnited States
NCT05303467
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Boston Scientific Corporation
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingUnited States
NCT04573140
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
University of Florida
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT03914768
Immune Modulatory DC Vaccine Against Brain Tumor
Shenzhen Geno-Immune Medical Institute
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingChina
NCT07093814
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/263 sites
RecruitingAustralia, Belgium, China, Czechia, Denmark, Spain
NCT06914128
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Bayer
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 26 sites
RecruitingChina
NCT07297212
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 16 sites
Not yet recruitingAustralia
NCT07739017
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Olivia Newton-John Cancer Research Institute
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT07902037
A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
Siren Biotechnology
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
By invitation onlyCanada
NCT05432518
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 1/215 sites
RecruitingSwitzerland, Spain, United States
NCT05765812
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
By invitation onlyUnited States
NCT06896110
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Andrew P. Groves
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States189 open trials
- China49 open trials
- France27 open trials
- Germany20 open trials
- Australia19 open trials
- United Kingdom19 open trials
- Canada17 open trials
- Netherlands16 open trials
- Switzerland15 open trials
- Italy14 open trials
- Denmark10 open trials
- Spain9 open trials
- Poland8 open trials
- Austria8 open trials
- Norway8 open trials
- Taiwan7 open trials
- Belgium6 open trials
- South Korea6 open trials
- Sweden6 open trials
- Singapore4 open trials
- New Zealand4 open trials
- Greece3 open trials
- Japan2 open trials
- Czechia2 open trials
- Puerto Rico2 open trials
- India2 open trials
- Russia2 open trials
- Portugal2 open trials
- Ireland2 open trials
- Uzbekistan1 open trial
- Israel1 open trial
- Hungary1 open trial
- Iran1 open trial
- Réunion1 open trial
- Argentina1 open trial
- Nigeria1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
What changed in the last 7 days
Registry facts, one per line, newest first.
Closed for recruitment
CUE-102 in Recurrent Glioblastoma
NCT06917885 · Phase 1 · United States
Source: ClinicalTrials.govNew in the registry
A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors
NCT07524140 · Phase 1 · Australia, Uzbekistan
Source: ClinicalTrials.govClosed for recruitment
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT04541082 · Phase 1 · United States
Source: ClinicalTrials.govClosed for recruitment
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
NCT01906385 · Phase 1/2 · United States
Source: ClinicalTrials.govClosed for recruitment
NCT06556563 · Phase 3 · Canada, Switzerland, Czechia, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT05902169 · Phase 3 · Austria, Belgium, Switzerland, Germany, Denmark, Spain
Source: ClinicalTrials.govNew in the registry
Preclinical Brain Tumor Models
NCT06045065 · No phase · France
Source: ClinicalTrials.govPhase changed: Phase 1 → Early Phase 1
Senicapoc and Perampanel for Newly Diagnosed Glioblastoma
NCT07284069 · Early Phase 1 · Denmark
Source: ClinicalTrials.govPhase changed: Phase 1 → Early Phase 1
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govOpened for recruitment
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govOpened for recruitment
NCT06556563 · Phase 3 · Canada, Switzerland, Czechia, Germany, Spain, France
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567 · Phase 1/2 · Czechia, Germany, Denmark, Spain, France, Italy
Source: ClinicalTrials.govClosed for recruitment
NCT06388733 · Phase 3 · Australia, Canada, Switzerland, Germany, Denmark, Spain
Source: ClinicalTrials.govPhase changed: Phase 1 → Early Phase 1
Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin
NCT05977738 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
NCT04762069 · Phase 2 · Switzerland, Spain, France, Italy, United States
Source: ClinicalTrials.govOpened for recruitment
NCT04443010 · Phase 1/2 · Switzerland, Germany, Italy
Source: ClinicalTrials.govClosed for recruitment
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
NCT04121455 · Phase 1/2 · Germany
Source: ClinicalTrials.gov
Show more
Phase changed: Phase 1/2 → Phase 2
NCT03175224 · Phase 2 · Australia, Canada, Spain, France, United Kingdom, Hungary
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
NCT02649582 · Phase 1/2 · Belgium
Source: ClinicalTrials.govOpened for recruitment
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
NCT04121455 · Phase 1/2 · Germany
Source: ClinicalTrials.govOpened for recruitment
NCT06388733 · Phase 3 · Australia, Canada, Switzerland, Germany, Denmark, Spain
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT04443010 · Phase 1/2 · Switzerland, Germany, Italy
Source: ClinicalTrials.govClosed for recruitment
PET-imaging of Two Vartumabs in Patients With Solid Tumors
NCT06645808 · Early Phase 1 · Netherlands
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
NCT02062827 · Phase 1 · United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Early Phase 1Ended 28 Oct 2026
Completed30 participants
NCT03893487
Fimepinostat in Treating Brain Tumors in Children and Young Adults
Phase 1/2Ended 16 Oct 2026
Phase 1Ended Sept 2026
Completed29 participants
NCT02062827
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Phase 2Ended Sept 2026
Paused19 participants
NCT05607407
Methimazole in Patients With Progressive Glioblastoma
Reason given: On hold per study team
Phase 1Ended 28 Sept 2026
Stopped early10 participants
NCT05533242
Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
Reason given: The remaining shelf-life of 1 component used in the manufacture of the study medication (SM) was insufficient to support further study conduct, and no additional material could be manufactured. Production of a new SM is planned for further projects.
Phase 1Ended 8 Sept 2026
Completed13 participants
NCT04295759
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Phase 1Ended 1 Sept 2026
Completed10 participants
NCT04385173
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
No phaseEnded Aug 2026
Withdrawn before start0 participants
NCT05410301
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
Reason given: PI leaving institution
Phase 1Ended 31 Aug 2026
Completed159 participants
NCT03423628
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Phase 1Ended 13 Aug 2026
Completed46 participants
NCT04201873
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Phase 2Ended 10 Aug 2026
Completed24 participants
NCT05183204
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Phase 1Ended 31 Jul 2026
Stopped early30 participants
NCT03170141
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
No reason given in the registry.
Phase 1Ended 30 Jul 2026
Completed16 participants
NCT03961971
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Phase 1Ended 20 Jul 2026
Completed32 participants
NCT03389802
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Phase 2Ended 13 Jul 2026
Completed2 participants
NCT06855628
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Phase 1Ended 9 Jul 2026
Completed11 participants
NCT04216329
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Phase 1Ended 1 Jul 2026
Withdrawn before start0 participants
NCT04854044
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Reason given: The P.I. is not prepared to move forward at this thime
No phaseEnded 30 Jun 2026
Completed42 participants
NCT06549075
Therapeutic Support to Strengthen Dignity, Mental Well-being and Quality of Life in Acute Palliative Care Patients.
Phase 2/3Ended 23 Jun 2026
Completed106 participants
2024-511542-39-00
An efficacy and safety study of 2-OHOA in patients with glioblastoma
Phase 1Ended 11 Jun 2026
Show more
Phase 1Ended 1 Jun 2026
Phase 1Ended 29 May 2026
Stopped early1 participant
NCT05627323
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
Reason given: IND application withdrawn
Phase 1/2Ended 27 May 2026
Completed27 participants
NCT03866109
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous system
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial. · Nature medicine, 2026
No phaseEnded 21 May 2026
Completed23 participants
NCT03477513
Personalized Radiation Therapy for GBM
- Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study. · Nature communications, 2026
No phaseEnded 1 May 2026
Completed44 participants
NCT03739372
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
Phase 1/2Ended 30 Apr 2026
No phaseEnded 17 Apr 2026
Stopped early57 participants
NCT05934630
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Reason given: The NCI will not extend the PBTC grant beyond March 31, 2026.
Phase 1/2Ended 15 Apr 2026
Completed32 participants
NCT03277638
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Phase 2Ended 9 Apr 2026
No phaseEnded 1 Apr 2026
Completed18 participants
NCT04730869
Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Phase 1Ended 28 Mar 2026
Completed35 participants
NCT07635173
SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas
Phase 2Ended 20 Mar 2026
Early Phase 1Ended 9 Mar 2026
Stopped early4 participants
NCT05091866
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Reason given: Review of Drug Supply
No phaseEnded 1 Mar 2026
Completed42 participants
NCT05431348
Effect of stRess and exeRcize on the Outcome After Chemo-Radiation
Phase 1Ended 1 Mar 2026
Completed7 participants
NCT06650605
Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma
No phaseEnded 28 Feb 2026
Completed1 participant
NCT07651020
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
No phaseEnded 19 Feb 2026
Completed981 participants
NCT04471844
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
Phase 1Ended 9 Feb 2026
Phase 1Ended 2 Feb 2026
Completed37 participants
NCT05938387
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
Phase 1/2Ended 2 Feb 2026
Completed54 participants
2022-501423-25-00
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma
Phase 1Ended 31 Dec 2025
Stopped early7 participants
NCT05557292
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Reason given: Drug no longer provided by sponsor
No phaseEnded Dec 2025
Paused1000 participants
NCT04219475
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
Reason given: Priority changes of the company
No phaseEnded 31 Dec 2025
Phase 3Ended Dec 2025
Paused234 participants
NCT02546102
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Reason given: Company is discussing with FDA to reinitiate the trial now.
No phaseEnded 31 Dec 2025
Phase 2/3Ended 23 Dec 2025
Phase 1Ended 22 Dec 2025
Completed21 participants
NCT06095375
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
Phase 2Ended 18 Dec 2025
Withdrawn before start0 participants
NCT04482933
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Reason given: The PBTC lost federal funding and will cease operations in March 2026.PBTC-061 was permanently closed on 10/24/2025 with no patients enrolled.
No phaseEnded 8 Dec 2025
Completed11 participants
NCT06451042
FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)
No phaseEnded 1 Dec 2025
Phase 2Ended 1 Dec 2025
Stopped early30 participants
NCT06359379
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Reason given: Terminated due to the sponsor's decision.
No phaseEnded 1 Dec 2025
Completed20 participants
NCT05735171
Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence
Phase 1Ended Nov 2025
Withdrawn before start0 participants
NCT04741984
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM
Reason given: Due to need to proceed with procedural changes with goals of improving the technical and economic feasibility.
Phase 1/2Ended 19 Nov 2025
Completed50 participants
NCT05275478
Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing
Phase 1/2Ended 13 Nov 2025
Completed33 participants
NCT03529448
TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Phase 4Ended 12 Nov 2025
Completed30 participants
NCT06625047
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
- Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy. · Contemporary clinical trials communications, 2026
Phase 3Ended 31 Oct 2025
Phase 2Ended 31 Oct 2025
Completed51 participants
NCT03532295
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Phase 1Ended 31 Oct 2025
Completed11 participants
NCT04968366
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
- Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial. · Nature communications, 2026
Phase 1Ended 25 Oct 2025
Not medical advice. fetched 10 Nov 2026